STUDY OF ACID REFLUX ASTHMA (SARA)

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究旨在确定胃酸反流（GERD）是否会导致哮喘，以及质子泵抑制剂（PPI）治疗是否会减少哮喘加重。这将作为一项多中心、随机、双盲、平行组临床试验进行，并采用安慰剂对照。在全国招募的400名患者中，预计有22名将在这里进行研究。主要结局指标是治疗期间哮喘加重率。阳性终点包括较低的哮喘发作率，较少的哮喘症状，更好的生活质量，更好的肺功能，更少的医疗保健使用，以及与安慰剂治疗相比改善的气道反应性。次要结局包括与峰值血流相关的可测量肺功能。PPI为埃索美拉唑（耐信）。这对有症状的哮喘患者有很大的潜在益处，他们可以从简单的医疗干预（质子泵抑制剂）中获益。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is designed to determine whether acid reflux (GERD) contributes to asthma and whether treatment with a proton-pump inhibitor (PPI) will reduce asthma exacerbations. This will be conducted as a multicenter, randomized, double-masked, parallel-group clinical trial, with a placebo control. Of 400 patients to be recruited nationally, 22 are expected to be studied here. The primary outcome measure is asthma exacerbation rate during treatment. Positive endpoints would include lower rate of asthma exacerbations, fewer asthma symptoms, better quality of life, better lung function, less health care use, and improved airway reactivity compared to those treated with a placebo. Secondary outcomes include measurable lung functions related to peak flow. The PPI is esomeprazole (Nexium). This is potentially of great benefit to symptomatic asthmatics who would benefit from a simple medical intervention (proton pump inhibitor).